FDA's Temple Discusses Measuring Efficacy When Mean Effect Is Limited

The distribution of positive results for individual patients, as well as a drug's mean benefit across the population of treated patients in a clinical trial, can be useful in assessing efficacy, CDER Deputy Director for Clinical Science Bob Temple indicated March 2 during a meeting on clinical trials for pulmonary arterial hypertension